GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Moderna Inc (CHIX:0QFd) » Definitions » Additional Paid-In Capital

Moderna (CHIX:0QFD) Additional Paid-In Capital : €908 Mil(As of Mar. 2025)


View and export this data going back to 2023. Start your Free Trial

What is Moderna Additional Paid-In Capital?


Moderna's quarterly additional paid-in capital increased from Sep. 2024 (€677 Mil) to Dec. 2024 (€827 Mil) and increased from Dec. 2024 (€827 Mil) to Mar. 2025 (€908 Mil).

Moderna's annual additional paid-in capital declined from Dec. 2022 (€1,107 Mil) to Dec. 2023 (€340 Mil) but then increased from Dec. 2023 (€340 Mil) to Dec. 2024 (€827 Mil).


Moderna Additional Paid-In Capital Historical Data

The historical data trend for Moderna's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Moderna Additional Paid-In Capital Chart

Moderna Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only 3,947.24 3,726.74 1,107.31 340.21 827.03

Moderna Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 448.04 586.20 676.65 827.03 908.35

Moderna Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Moderna Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Moderna's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Moderna Business Description

Industry
Address
325 Binney Street, Cambridge, MA, USA, 02139
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

Moderna Headlines

No Headlines